SecBot SecBot

RYTM drug pipeline

$115.02
+4.7% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±4.6%
1-day, median of 8 events
IV rank
No data
No current options data
Rated drugs
1
1 bullish
Phase 3 trials
2
1 with results posted

Drugs

soonest catalyst first

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, bull and bear case and thesis.

Subscribe for Full Access

Other drugs in filings and trials

no drug report yet

Past FDA events & how the stock moved

8 events
DateDrugEvent1 day5 days
Mar 26, 2026IMCIVREEApproval−10.4%+2.0%
Mar 20, 2026IMCIVREEPDUFA decision−6.3%−16.0%
Mar 19, 2026IMCIVREEApproval+1.9%−4.6%
Dec 20, 2025IMCIVREEPDUFA decision+0.7%+0.4%
Dec 20, 2025IMCIVREEPriority review+0.7%+0.4%
Aug 20, 2025IMCIVREENDA filed+4.6%+5.3%
Aug 20, 2025IMCIVREEPriority review+4.6%+5.3%
Nov 25, 2020IMCIVREEApproval+26.2%+24.9%

Clinical trials

3 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
SetmelanotideOpen-Label Extension Study of SetmelanotidePhase 3Completed28Jun 24, 2026
BivamelagonA Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic ObesityPhase 2Completed · results28Feb 9, 2026
SetmelanotideEMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R PathwayPhase 3Completed · results296Dec 19, 2025